Clareo Health | Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who completed 8-week short-term treatment study, 13267A (NCT01140906), for Major Depressive Episode immediately prior to enrolment in this extension study
You may not be if
Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV TR)
Female patients of childbearing potential who are not using effective contraception
Use of any psychoactive medication
The patient, in the investigator's clinical judgment, has a significant risk of suicide.
